VACC - Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna
- Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals.
- Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda.
- RNA interference is a proven science with dependent delivery vehicles being used like GalNAc or others developed by Arrowhead Pharma like TRiM.
- Acquisition pulls in 5 ongoing programs in trials, 20 preclinical research programs and 5 developed partnerships.
For further details see:
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker Dicerna